CN109497563A - 白癜风专用型临床营养配方及其制备方法 - Google Patents
白癜风专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN109497563A CN109497563A CN201811237134.XA CN201811237134A CN109497563A CN 109497563 A CN109497563 A CN 109497563A CN 201811237134 A CN201811237134 A CN 201811237134A CN 109497563 A CN109497563 A CN 109497563A
- Authority
- CN
- China
- Prior art keywords
- parts
- leucoderma
- powder
- tailored version
- clinical nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 59
- 230000035764 nutrition Effects 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title description 10
- 229940088594 vitamin Drugs 0.000 claims abstract description 30
- 229930003231 vitamin Natural products 0.000 claims abstract description 30
- 235000013343 vitamin Nutrition 0.000 claims abstract description 30
- 239000011782 vitamin Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 230000035622 drinking Effects 0.000 claims abstract description 19
- 235000008216 herbs Nutrition 0.000 claims abstract description 19
- 230000010354 integration Effects 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 239000004615 ingredient Substances 0.000 claims abstract description 15
- 235000005911 diet Nutrition 0.000 claims abstract description 13
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 13
- 230000037213 diet Effects 0.000 claims abstract description 12
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 118
- 235000013350 formula milk Nutrition 0.000 claims description 38
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 28
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 26
- 235000015097 nutrients Nutrition 0.000 claims description 23
- 210000004185 liver Anatomy 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 14
- 108010038807 Oligopeptides Proteins 0.000 claims description 14
- 102000015636 Oligopeptides Human genes 0.000 claims description 14
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 14
- 229920001202 Inulin Polymers 0.000 claims description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 13
- 241000209140 Triticum Species 0.000 claims description 13
- 235000021307 Triticum Nutrition 0.000 claims description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 13
- 229940029339 inulin Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 244000144730 Amygdalus persica Species 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 12
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 11
- 235000010469 Glycine max Nutrition 0.000 claims description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 240000007651 Rubus glaucus Species 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 241000208671 Campanulaceae Species 0.000 claims description 9
- 241000237502 Ostreidae Species 0.000 claims description 9
- 235000020636 oyster Nutrition 0.000 claims description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 8
- 241000408747 Lepomis gibbosus Species 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 235000015277 pork Nutrition 0.000 claims description 8
- 235000020236 pumpkin seed Nutrition 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 7
- 241000206575 Chondrus crispus Species 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 235000010755 mineral Nutrition 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 5
- 244000111489 Gardenia augusta Species 0.000 claims description 4
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 4
- 235000008599 Poria cocos Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 244000131360 Morinda citrifolia Species 0.000 claims description 3
- 108010001441 Phosphopeptides Proteins 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000020243 first infant milk formula Nutrition 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000017524 noni Nutrition 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 241000781608 Scolopia zeyheri Species 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 35
- 239000003814 drug Substances 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 26
- 206010047642 Vitiligo Diseases 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000009098 adjuvant therapy Methods 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 20
- 230000006870 function Effects 0.000 description 18
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 14
- 210000002752 melanocyte Anatomy 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229930003427 Vitamin E Natural products 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 235000019165 vitamin E Nutrition 0.000 description 10
- 229940046009 vitamin E Drugs 0.000 description 10
- 239000011709 vitamin E Substances 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 235000013312 flour Nutrition 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 238000001126 phototherapy Methods 0.000 description 8
- 239000011691 vitamin B1 Substances 0.000 description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 238000002651 drug therapy Methods 0.000 description 7
- 229960000304 folic acid Drugs 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- 229940055726 pantothenic acid Drugs 0.000 description 7
- 239000011713 pantothenic acid Substances 0.000 description 7
- 235000019161 pantothenic acid Nutrition 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000011715 vitamin B12 Substances 0.000 description 7
- 239000011716 vitamin B2 Substances 0.000 description 7
- 239000011726 vitamin B6 Substances 0.000 description 7
- 108010073771 Soybean Proteins Proteins 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000011554 guinea pig model Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 235000019710 soybean protein Nutrition 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000003914 Cholinesterases Human genes 0.000 description 5
- 108090000322 Cholinesterases Proteins 0.000 description 5
- 240000005717 Dioscorea alata Species 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 5
- 108010062431 Monoamine oxidase Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940048961 cholinesterase Drugs 0.000 description 5
- 235000004879 dioscorea Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 4
- 240000003582 Platycodon grandiflorus Species 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000007215 black sesame Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035614 depigmentation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000003132 food thickener Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000003694 hair properties Effects 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 3
- 229960004023 minocycline Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 241000371652 Curvularia clavata Species 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000286838 Eclipta prostrata Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- -1 Hydroxymethylglutaryl Chemical group 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 2
- 240000001740 Momordica dioica Species 0.000 description 2
- 235000018365 Momordica dioica Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 244000226566 Psoralea corylifolia Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000002547 Rosa roxburghii Species 0.000 description 2
- 235000000640 Rosa roxburghii Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241001521901 Tribulus lanuginosus Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 241000522215 Dipteryx odorata Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 241000592274 Polypodium vulgare Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000353135 Psenopsis anomala Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000027498 hoarse voice Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- HTUMBQDCCIXGCV-UHFFFAOYSA-N lead oxide Chemical compound [O-2].[Pb+2] HTUMBQDCCIXGCV-UHFFFAOYSA-N 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N lead(II) oxide Inorganic materials [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 229940048874 minocycline 100 mg Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种白癜风专用型临床营养配方,包括如下组分及其重量份数:20‑26份蛋白质、32‑44份碳水化合物、16‑22份膳食纤维、0.01‑0.04份微量元素、0.005‑0.03份脂溶性维生素、0.1‑0.25份水溶性维生素、0.1‑11份膳食精华、0.2‑18份药食同源成分以及0.01‑1.1份新资源食品。本发明还提供上述临床营养配方的制备方法。本发明的白癜风专用型临床营养配方既能够为白癜风患者提供手术前营养支持,又能够为白癜风患者提供手术后组织修复的营养辅助治疗,还能够缓解治疗白癜风的药物的毒副作用以及患者的心理和精神上的负担。
Description
技术领域
本发明涉及临床营养配方领域,尤其涉及一种白癜风专用型临床营养配方及其制备方法。
背景技术
白癜风是一种常见的后天性限局性或泛发性皮肤色素脱失病,其由于皮肤的黑素细胞功能消失引起,但机制还不清楚。全身各部位均有可能发生白癜风,常见于指背、腕、前臂、颜面、颈项及生殖器周围等;女性外阴部亦可发生,并以青年妇女居多。
白癜风的发病机制为:白癜风是种常见的获得性色素脱失性皮肤粘膜病,以表皮黑色素细胞受损而出现色素脱失斑为特征,病因复杂。
目前针对白癜风的治疗方法有(1)物理治疗、(2)手术治疗、(3)辅助治疗、(4)药物治疗、(5)神经化学治疗、(6)联合治疗。
(1)目前物理治疗主要包括:光疗法和光化学疗法,其中:
光疗法又称窄谱中波紫外线照射疗法(NB—UVB),窄谱中波紫外线(NB-UB)是一组波长在311-322nm的射线,其光谱窄、能量大、针对性强、色素恢复一致,几乎不走红斑,对儿童孕妇的治疗都安全,被认为是治疗白癜风热别是泛发性白癜风安全有效的一线疗法。
光化学疗法是一种通过口服或外用呋喃香豆类药物-补骨脂素等化学光敏剂后配合长波紫外线照射的治疗方法,但是不良反应居多,包括白内障、胃肠道反应、光毒性,并且可以造成正常皮肤和再着色皮肤处严重色差。其包括308nm准分子激光及308nm准分子光和氦氖激光;308nm准分子激光及308nm准分子光是在NB-UVB的基础上发展起来的高能单光源靶向治疗方法,具有高效性、安全性及可选择性作用于病变皮损,减少周围组织及皮损光照量等特点,在临床上得到广泛的应用,是治疗白癜风最佳以及不良反应最少的光疗方法;氦氖激光是一种波长在632.8nm的低能量激光。其治疗白癜风的机制主要是与其刺激角质形成细胞和角质形成细胞分泌的神经生长因子有关。
(2)手术治疗是一种适用于药物和物理治疗无效的稳定期或节段性白癜风的治疗方法,对手、足、嘴唇、乳头等难治部位也可以采取手术治疗的方法。常用的手术方法有自体表皮移植法、微小皮片移植法、自体非培养表皮细胞悬液移植法等,但手术治疗会导致复色失败。
(3)辅助治疗包括遮盖疗法和脱色疗法:遮盖疗法虽然对白癜风没有治疗作用,仅仅可以用来减轻白癜风患者的心理负担,但能够提高患者生活质量,缺点是可能发生同形反应、褪色及颜色与正常肤色不匹配等;脱色疗法适用于白斑面积过大及各种复色治疗方法无效的患者。
(4)药物治疗从用药范围上分为局部用药和系统用药,从用药选择上可分为常规用药、非常规用药、生物制剂、中医用药、中西医联合用药,其中:
常规用药包括糖皮质激素、钙调磷酸抑制剂、维生素D衍生物、抗氧化剂:
糖皮质激素和钙调磷酸抑制剂是治疗白癜风的一线外用药,这两种药物均可抑制细胞免疫反应;
维生素D的衍生物可促进黑素细胞的分化、粘附和迁移,参与调控黑素细胞的生理功能,增强酪氨酸激酶活性,目前临床治疗药物主要有他卡西醇联合光疗法治疗可促进复色并降低光照剂量,但尚未见研究报道单用维生素D类衍生物对复色效果有益;
氧化应激是白癜风发生发展的始动因素,抗氧化剂可改善氧化应激水平,对白癜风的治疗具有重要作用,临床上常用于治疗白癜风的抗氧化剂有维生素E、辅酶Q、水龙骨提取物、α-硫辛酸和银杏叶提取物等;有报道口服抗氧化剂或外用抗氧化软膏与光疗联合作用治疗效果优于单用光疗,并且口服银杏叶提取物单药治疗白癜风可获得一定疗效,但仍然需要进一步的临床研究;
非常规用药包括米诺环素、前列腺素、辛伐他丁、酪氨酸激酶(JAK)抑制剂、肿瘤坏死因子-α(TNF-α)抑制剂、他汀类药物、甲氨蝶呤:
米诺环素具有抗炎、免疫调节和抗氧化作用,然而实验证明与口服米诺环素相比,NB-UVB对稳定白癜风患者病情更有益,另有研究表明治疗进展期白癜风,口服米诺环素100mg/d与地塞米松微脉冲疗法无差异;
前列腺素可增加酪氨酸酶活性,促进黑素细胞增殖,刺激黑素小体及黑素细胞的发育、成熟,从而促进黑素代谢;
辛伐他丁属于羟甲基戊二酸单酰辅酶A(HMG-CoA)还原酶抑制剂,其具有经典的调节血脂的功能外,还具有一定的免疫调节、抗炎和抗氧化作用,研究发现,辛伐他丁可通过抗氧化作用保护白癜风黑色素细胞抵抗氧化应激损伤,为辛伐他丁应用于临床白癜风治疗提供了新的理论依据;
γ-干扰素诱导的角质形成细胞通过分泌大量CXC趋化因子配体10(CXCL10)等趋化因子参与了白癜风的发病,而酪氨酸激酶(JAK)抑制剂则可以抑制IFN-γ信号传导从而下调CXCL10的表达,酪氨酸激酶(JAK)应用于患者后对患者的面部的情况改善的比较明显,并且近期的研究还发现,JAK还需要联合光疗进行配合,与单独光疗相比,JAK抑制剂联合光疗可以降低患者的照光剂量;
TNF-α在白癜风的发生发展中有着重要作用,白癜风患者皮损处TNF-α水平较高,而TNF-α抑制剂有望成为治疗白癜风的新靶点;
他汀类为传统治疗高胆固醇血症及动脉硬化的特效药物,但是近几年的研究发现,他汀类药物可下调参与细胞免疫反应的多种粘附分子的表达,以及抗原递呈细胞(APC)中的主要组织相容性复合体(MHC)2、T细胞趋化因子受体和包括肿瘤坏死因子-α(TNF-α)、干扰素、白介素-6、白介素-2在内的多种炎症细胞因子的表达,它们也是抗氧化剂,能阻断一氧化氮合成酶,增加调节标记物IL-2和TGF-β的产生,临床前期数据表明他汀类药物通过阻止皮肤自身反应性细胞毒性T细胞的增殖,以及通过降低IFN-γ的产生,来预防和阻断色素脱失;
甲氨蝶呤药因其用于炎症性、免疫介导性疾病和炎性肠病而被知晓,随着研究的深入正逐渐用于白癜风的治疗;
生物制剂:最近有报道使用一种口服的Janus激酶1/3抑制剂-枸橼酸托法替尼,成功治疗了1例累及10%体表面积(BSA)的女性泛发性白癜风患者,5个月后出现明显的复色效果,无不良反应发生;
中医用药:目前临床上中医常采用祛风通络、补益肝肾、活血化瘀三大原则来治疗白癜风。最近一些研究发现加味桃红四物汤的含药血清能上调黑素细胞的酪氨酸酶活性,提高黑素含量,促进黑素增殖,说明中药治疗白癜风与其酪氨酸酶活性的影响及黑素细胞作用有关,其他研究还表明中药治疗白癜风的有效性可能与其它免疫调节有关;
(5)神经化学治疗:神经化学物质对白癜风的发病也有一定作用,如去甲肾上腺素和肾上腺素等神经化学因子在体外能使两栖类和鱼类的黑素细胞变白,酚类物质的聚集及神经化学物质的异常都会不同程度上导致黑素细胞受损而诱发黑色素细胞凋亡,导致黑素细胞缺乏;因此,最近几年来,有学者提出神经化学因子与自身免疫联合学说,对临床指导具有重要意义;
(6)联合治疗用于当阶段单一药物、物理或是手术疗法都无法取得良好的治疗效果时,两种以及多种方法的联合治疗日益成为治疗的首选方案,治疗效果更加明显。
中国专利CN102940799A公开了一种治疗白癜风的中药组合物及其制备方法,其主要包括外用和内服两种配方综合治疗,外用配方采用熟地、女贞子、墨旱莲、肉桂、自然铜、红花、川芎、菟丝子、制首乌、补骨脂、蛇床子、雄黄、硫黄、白鲜皮、白附子、密陀僧和白酒、黑米醋按一定重量份比例混合;内服配方采用白蒺藜子、姜黄、旱莲草、补骨脂、黑芝麻、制何首乌和白芷按一定重量份比例混合制成。该专利的组分均为中药成分,不具有为患者提供营养支持的功能,且中药成分在一定程度上会对肠胃造成损伤,进而影响患者对营养的吸收。
中国专利CN106722663A公开了一种用于白癜风食疗的营养粉及其制备方法,其包含以下重量份数的原料:栗子:20-50份;薏仁:30-60份;无花果:20-50份;山楂:10-30份;枸杞:5-20份;沙苑子:3-10份;覆盆子:3-10份;白蒺藜:5-15份;芝麻:3-10份;瓜子:3-10份。该专利的营养粉虽然为患者提供了营养支持,但缺少基础营养成分,使提供的营养支持不能做到全面、均衡;并且,该专利的营养粉并不具备临床治疗的营养辅助的功能。
目前尚未明确白癜风的确切发病机制和因素,所采取的都是对症治疗,而现今尚未有针对于白癫风的药物治疗的毒副作用缓解、手术治疗的辅助营养支持以及手术后组织修复的营养支持的产品出现。
发明内容
本发明所要解决的技术问题是:针对现有技术的缺陷,提供一种白癜风专用型临床营养配方及其制备方法,既能够为白癜风患者提供手术前营养支持,又能够为白癜风患者提供手术后组织修复的营养辅助治疗,还能够缓解治疗白癜风的药物的毒副作用以及患者的心理和精神上的负担。
本发明为解决上述技术问题采用以下技术方案:
本发明的第一个目的是提供一种白癜风专用型临床营养配方,包括如下组分及其重量份数:20-26份蛋白质、32-44份碳水化合物、16-22份膳食纤维、0.01-0.04份微量元素、0.005-0.03份脂溶性维生素、0.1-0.25份水溶性维生素、0.1-11份膳食精华、0.2-18份药食同源成分以及0.01-1.1份新资源食品;
其中,所述药食同源成分包括茯苓、栀子、黑芝麻、薄荷、桔梗、山药、牡蛎、桃仁、覆盆子、枸杞子中的至少一种;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、小麦低聚肽、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
为了优化上述的技术方案,本发明采取的技术措施还包括:
进一步地,所述蛋白质包括乳清蛋白粉、大豆分离蛋白、全脂奶粉、脱脂奶粉、全蛋粉、乳铁蛋白、牛初乳、氨基酸和蛋白肽中的至少一种;其中,所述氨基酸包括L-赖氨酸-L-谷氨酸、L-谷氨酸、L-精氨酸、L-色氨酸、L-谷氨酰胺、牛磺酸、L-缬氨酸、L-异亮氨酸、L-亮氨酸中的至少一种;所述蛋白肽包括大豆低聚肽、蚕蛹蛋白肽、海洋鱼低聚肽粉、可乐肽、氨基肽、鱼胶原蛋白肽、卵白蛋白肽中的至少一种。
进一步地,所述蛋白质包括大豆分离蛋白和乳清蛋白粉中的至少一种。
进一步地,所述碳水化合物包括果糖、冰糖、乳糖、麦芽糊精、木薯淀粉、抗性淀粉中的至少一种。
进一步地,所述碳水化合物至少包括30-40份的麦芽糊精;更优选为,所述碳水化合物至少包括30-35份的麦芽糊精。
进一步地,所述膳食纤维包括菊粉、魔芋粉、低聚半乳糖、低聚果糖、低聚异麦芽糖、大豆多糖、环糊精、抗性糊精、大豆纤维中的至少一种。
进一步地,所述膳食纤维包括低聚果糖和菊粉中的至少一种;更进一步地,所述膳食纤维至少包括菊粉,所述菊粉的重量份数为10-16份。
进一步的,所述膳食纤维包括10-12份低聚果糖和10-16份菊粉。
进一步地,所述微量元素包括葡萄糖酸亚铁、硫酸亚铁、碘化钾、柠檬酸锌、葡萄糖酸锌、亚硒酸钠、硫酸铜、葡萄糖酸铜、硫酸铬、氯化铬、葡萄糖酸锰、硫酸锰、和钼酸钠中的至少一种。
进一步地,所述微量元素包括铁、锌和铜,其中:所述微量元素中铜的重量份数为0.0003-0.001份,锌的重量份数为0.01-0.02份。
进一步地,所述脂溶性维生素包括维生素A、β-胡萝卜素、维生素D3、维生素E、维生素K1中的至少一种。
更进一步地,所述脂溶性维生素至少包括维生素E,所述维生素E的重量份数为0.005-0.03份;更优选为,所述维生素E的重量份数为0.001-0.002份。
进一步地,所述水溶性维生素包括维生素B1、维生素B2、维生素B6、维生素B12、维生素C、泛酸、叶酸、烟酸、胆碱、肌醇、生物素中的至少一种。
更进一步地,所述水溶性维生素至少包括维生素B1、维生素B2、维生素B6、维生素B12、烟酸、叶酸、泛酸,所述维生素B1的重量份数为0.002-0.003份、维生素B2的重量份数为0.001-0.002份、维生素B6的重量份数为0.002-0.003份、维生素B12的重量份数为0.000001-0.00001份、烟酸的重量份数为0.01-0.02份、叶酸的重量份数为0.0001-0.001份、泛酸的重量份数为0.001-0.01份。
进一步地,所述膳食精华包括谷类、豆类、薯类、蔬菜类、菌藻类、坚果种子类、鱼虾类、禽畜肉类、水果类中的至少一种;其中,所述谷类包括大米粉、小米粉、黑米粉、薏米粉、玉米粉、小麦胚芽粉、燕麦粉、荞麦粉中的至少一种;所述豆类包括豌豆粉、绿豆粉、黑豆粉、红豆粉、大豆粉中的至少一种;所述薯类主要由淮山粉组成;所述蔬菜类包括胡萝卜粉、白萝卜粉、苦瓜粉、南瓜粉、菠菜粉、番茄粉、西兰花粉、苦瓜粉中的至少一种;所述菌藻类包括香菇粉、海带粉、黑木耳粉、银耳粉中的至少一种;所述坚果种子类包括南瓜籽粉、莲子粉中的至少一种;所述鱼虾类包括三文鱼粉、鳕鱼粉中的至少一种;所述禽畜肉类包括鸡肉粉、牛肉粉、猪肝粉中的至少一种;所述水果类包括红枣粉、奇异果粉、桂圆粉、苹果粉、樱桃粉、柑橘粉、雪梨粉中的至少一种。
进一步地,所述膳食精华包括大豆粉、南瓜籽粉、海带粉、香菇粉、黑木耳粉、猪肝粉;更进一步地,所述膳食精华包括6-8份大豆粉、0.1-1份南瓜籽粉、0.1-0.5份海带粉、0.1-0.5份香菇粉、0.1-0.5份黑木耳粉、0.1-0.5份猪肝粉。
进一步地,所述药食同源成分包括黑芝麻、覆盆子、枸杞子、桔梗、山药、牡蛎、桃仁;更进一步地,所述药食同源成分中各组分的重量份数为:黑芝麻10-15份、覆盆子0.1-0.5份、枸杞子0.1-0.5份、桔梗0.1-0.5份、山药0.1-0.5份、牡蛎0.1-0.5份、桃仁0.1-0.5份。
进一步地,所述新资源食品包括γ-氨基丁酸和小麦低聚肽;更进一步地,所述新资源食品中各组分的重量份数为:γ-氨基丁酸0.01-0.1份、小麦低聚肽0.1-1份。
本发明的第二个目的是提供一种上述白癜风专用型临床营养配方的制备方法,包括如下步骤:
步骤1,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤2,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤3,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳食精华以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤4,将步骤1~3所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤5,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~3的顺序可相互更换。
为了优化上述的制备方法,本发明采取的技术措施还包括:
进一步地,所述步骤5中可选择性地增加适量的食品增稠剂和食品添加剂。所述食品增稠剂选自瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、阿拉伯胶中的至少一种;所述食品添加剂选自阿斯巴甜、食用香精香料、红糖中的至少一种;更优选为卡拉胶、阿拉伯胶、瓜尔胶、阿斯巴甜、食用香精香料。
进一步地,上述白癜风专用型临床营养配方的干法工艺的制备方法的操作步骤均需在惰性气体的保护下进行,所使用的惰性气体为氮气、氩气、氦气等。在惰性气体的保护下进行上述操作步骤可以防止产生粉末爆炸的危险。
本发明中采用包括黑芝麻、覆盆子、枸杞子、桔梗、山药、牡蛎、桃仁的药食同源成分,上述成分配伍增效后具有促进营养吸收、改善新陈代谢、增强免疫能力、抗氧化之效,有助于为白癜风患者提供营养支持和营养辅助治疗,并且还具有降血压、安稳心神等功效,有助于减轻患者的心理和精神上的负担。
黑芝麻具有补肝肾、益精血、润肠燥之效,其含有多种人体必需氨基酸,在维生素E和维生素B1的作用参与下,能加速人体的代谢功能;还具有抗炎作用,灭菌的芝麻油涂布皮肤黏膜,有减轻刺激、促进炎症恢复等作用。
覆盆子具有补肝肾、缩小便、助阳、固精、明目之效,且覆盆子果肉具有含量超过1%的总氨基酸,其营养丰富,易于人体吸收,具有改善新陈代谢、提高免疫力的作用;覆盆子富含鞣花酸,是一种具有抗氧化作用的多酚化合物,有助于白癜风的治疗。
枸杞子具有补肾益精、养肝明目、补血安神、生津止渴、润肺止咳之效;其富含枸杞多糖,具有生理活性,能够增强非特异性免疫功能,提高抗病能力,抑制肿瘤生长和细胞突变;枸杞多糖能够明显提高吞噬细胞的吞噬功能,提高淋巴细胞的增殖能力,具有调节免疫反应的功能,并可以通过神经--内分泌--免疫调节网络发挥抗癌作用。
桔梗宣肺、利咽、祛痰、排脓,用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃;粗桔梗皂甙有抗炎作用以及抑制胃液分泌、抗溃疡的作用,粗制桔梗皂甙在低于1/5半数致死量的剂量时有抑制大鼠胃液分泌和抗消化性溃疡作用。
山药含有蛋白质、维生素、淀粉、钙磷等人体必需的营养素,据药理研究山药中的黏多糖,可以刺激和调节人体的免疫系统,有抗肿瘤、抗病毒、抗衰老的作用;山药含有的大量黏液蛋白、维生素及微量元素,能有效阻止血脂在血管壁的沉淀,预防心血疾病,有降血压、安稳心神的功效;山药中的皂甙可以调节血压、降血糖、降血脂、抑制肿瘤,同时也有利于胃部的保护,粘液所特有的粘稠质地可以对胃壁形成一层保护,减轻胃黏膜的压力。
牡蛎咸寒质重、入肝经,有平肝潜阳、益阴之功,可用于心神不安,惊悸失眠,《伤寒论》记载该品质重能镇,有安神之功效,用于治疗心神不安、惊悸怔忡、失眠多梦等症。
桃仁味苦甘而性平,能入心、肝、大肠,活血祛瘀作用甚广,可用治瘀血阻滞各种敝症;具有活血祛瘀、润肠通便、止咳平喘、祛瘀血、抗炎、抗过敏之效。
本发明中采用γ-氨基丁酸和小麦低聚肽的新资源食品,上述成分配伍增效后具有调节情绪、缓解精神压力、增强免疫能力、维持肠道功能、缓解药物治疗的毒副作用等功效,有利于白癜风的恢复治疗。
γ-氨基丁酸具有活化大脑、抗癫痫和润泽肌肤的作用;医学研究发现γ-氨基丁酸具有降血压、镇痛、抗焦虑、抗疲劳、调节情绪的作用,精神压力会使脑中γ-氨基丁酸的积累异常困难,缺乏时会产生焦虑、疲劳失眠等症状。
小麦低聚肽具有促进脂肪代谢、抗疲劳、抗氧化和利于皮肤组织修复的作用;还能够增强免疫系统的功能,维持胃肠道黏膜结构完整性,参与合成谷胱甘肽(谷胱甘肽是一种重要的抗氧化剂),改善脑功能,维持肾脏、胰腺、胆囊和肝脏的正常功能。
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:
添加10-16份菊粉,菊粉可以促进各种矿物质的吸收,而矿物质的吸收利于体内对黑色素的合成,添加于本发明的临床营养配方中,有助于为白癜风患者提供手术后组织修复的营养辅助治疗。
添加0.0003-0.001份铜与0.01-0.02份锌:体内铜离子含量增高可以在体内合成铜蓝蛋白,有助于黑色素的合成;锌可用于维护上皮组织的完整和支持粘膜和皮肤组织的修复与完好,与铜协同配合,可用于协助铜蓝蛋白保持体内的稳定。
本发明通过选用合理配比的基础营养素,同时添加具有促进营养吸收、改善新陈代谢、增强免疫能力、抗氧化、调节情绪、缓解精神压力、利于皮肤组织修复的膳食纤维、药食同源成分以及新资源食品等特殊营养物质,并调整其配比与基础营养素进行配伍增效,使的本发明的白癜风专用型临床营养配方更易于被白癜风患者吸收,从而充分发挥各组分的功效,为白癜风患者提供手术前营养支持和手术后组织修复的营养辅助治疗,并缓解治疗白癜风的药物的毒副作用以及患者的心理和精神上的负担。
具体实施方式
本发明提供了一种白癜风专用型临床营养配方,包括如下组分及其重量份数:20-26份蛋白质、32-44份碳水化合物、16-22份膳食纤维、0.01-0.04份微量元素、0.005-0.03份脂溶性维生素、0.1-0.25份水溶性维生素、0.1-11份膳食精华、0.2-18份药食同源成分以及0.01-1.1份新资源食品;其中,所述药食同源成分包括茯苓、栀子、黑芝麻、薄荷、桔梗、山药、牡蛎、桃仁、覆盆子、枸杞子中的至少一种;其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、小麦低聚肽、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
下面结合实施例对本发明的技术方案做进一步的详细说明。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
实施例1
本发明所述的白癜风专用型临床营养配方包括大豆分离蛋白10g、乳清蛋白粉10g、麦芽糊精32g、低聚果糖10g、菊粉10g、铁16.8mg、锌14.3mg、铜300μg、维生素E 21.9mg、维生素B12.1mg、维生素B21.5mg、维生素B62.05mg、维生素B125.1μg、烟酸15.9mg、叶酸821μg、泛酸6mg、大豆粉7.1g、南瓜籽粉1g、海带粉0.5g、香菇粉0.5g、黑木耳粉0.5g、猪肝粉0.5g、黑芝麻粉15g、覆盆子0.5g、枸杞子0.5g、桔梗粉0.5g、山药粉0.5g、牡蛎粉0.5g、桃仁粉0.5g、小麦低聚肽1g、γ-氨基丁酸0.1g。
实施例2
本发明所述的白癜风专用型临床营养配方包括大豆分离蛋白10g、乳清蛋白粉10g、麦芽糊精36g、低聚果糖10g、菊粉10g、铁16.8mg、锌14.3mg、铜300μg、维生素E 21.9mg、维生素B12.1mg、维生素B21.5mg、维生素B62.05mg、维生素B125.1μg、烟酸15.9mg、叶酸821μg、泛酸6mg、大豆粉7.1g、南瓜籽粉0.1g、海带粉0.1g、香菇粉0.1g、黑木耳粉0.1g、猪肝粉0.1g、黑芝麻粉15g、覆盆子0.1g、枸杞子0.1g、桔梗粉0.1g、山药粉0.1g、牡蛎粉0.1g、桃仁粉0.1g、小麦低聚肽1g、γ-氨基丁酸0.1g。
实施例3
本发明所述的白癜风专用型临床营养配方包括大豆分离蛋白10g、乳清蛋白粉10g、麦芽糊精37g、低聚果糖10g、菊粉10g、铁16.8mg、锌14.3mg、铜300μg、维生素E 21.9mg、维生素B12.1mg、维生素B21.5mg、维生素B62.05mg、维生素B125.1μg、烟酸15.9mg、叶酸821μg、泛酸6mg、大豆粉7.1g、南瓜籽粉0.1g、海带粉0.1g、香菇粉0.1g、黑木耳粉0.1g、猪肝粉0.1g、黑芝麻粉15g、覆盆子0.1g、枸杞子0.1g、桔梗粉0.1g、山药粉0.1g、牡蛎粉0.1g、桃仁粉0.1g、小麦低聚肽0.1g、γ-氨基丁酸0.01g。
实施例4
本发明所述的白癜风专用型临床营养配方包括大豆分离蛋白10g、乳清蛋白粉10g、麦芽糊精32g、低聚果糖10g、菊粉10g、铁16.8mg、锌14.3mg、铜300μg、维生素E 21.9mg、维生素B12.1mg、维生素B21.5mg、维生素B62.05mg、维生素B125.1μg、烟酸15.9mg、叶酸821μg、泛酸6mg、大豆粉7.1g、南瓜籽粉1g、海带粉0.5g、香菇粉0.5g、黑木耳粉0.5g、猪肝粉0.5g、黑芝麻粉15g、栀子0.5g、茯苓0.5g、桔梗粉0.5g、山药粉0.5g、牡蛎粉0.5g、桃仁粉0.5g、玛咖粉0.1g、γ-氨基丁酸0.1g。
实施例5
一种如实施例1~实施例4所述的白癜风专用型临床营养配方的制备方法如下:
1)制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
2)制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
3)将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳食精华以及新资源食品分别制备成粒径为150~250μm的粉末;
4)将步骤1~3所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
5)根据常规技术手段将步骤4)中的配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种。
在步骤5)中,可选择性地增加适量的食品增稠剂和食品添加剂。所述食品增稠剂为瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、阿拉伯胶中的至少一种,所述食品添加剂为阿斯巴甜、食用香精香料、红糖中的至少一种;更优选卡拉胶、阿拉伯胶、瓜尔胶、阿斯巴甜、食用香精香料。
上述操作步骤均需在惰性气体的保护下进行,比如氮气、氩气、氦气等,以防止产生粉末爆炸的危险。
按照所述配方可制备成粉状、颗粒状、胶囊状、片剂状、饮料等类别。
实施例6
本实施例为验证实施例。
本验证实施例通过验证本发明所述的白癜风专用型临床营养配方对白癜风豚鼠模型的治疗作用以验证其对白癜风患者的影响。本实施例采用实施例1-4的配方制备的营养粉以及下述对比例:
对照组:纯化水;
实验组1:采用实施例1的营养配方制备的营养粉,并稀释溶解;
实验组2:采用实施例2的营养配方制备的营养粉,并稀释溶解;
实验组3:采用实施例3的营养配方制备的营养粉,并稀释溶解;
实验组4:采用实施例4的营养配方制备的营养粉,并稀释溶解;
实验组5:采用实施例1的营养配方中删除药食同源成分后制备的营养粉,并稀释溶解;
实验组6:采用实施例1的营养配方中删除新资源食品后制备的营养粉,并稀释溶解。
白癜风豚鼠模型采用健康黑色豚鼠制备,取健康黑色豚鼠共140只,雌雄各半,使用电动剃须刀剃取背部毛面积4cm*4cm,并在脱毛区域涂0.5%的氢醌0.05mL,Bid,连续60d,制备得到实验性白癜风豚鼠模型;另外,取健康黑色豚鼠共20只,雌雄各半,使用电动剃须刀剃取背部毛面积4cm*4cm,并在脱毛区域涂等量纯化水,作为空白组。
将上述实验性白癜风豚鼠模型随机等分成7组,每组20只,分别作为对照组、实验组1、实验组2、实验组3、实验组4、实验组5、实验组6,每组分别从造模第11天起灌胃各组对应的纯化水或营养剂,每天灌胃1次,每次灌胃量按2mL/100g(实验组1-实验组6所对应的营养粉量为每毫升营养剂中溶解0.1g-0.11g),连续灌胃50d;
在灌胃上述纯化水或营养剂的同时,取市售白癜风胶囊,将胶囊内容物用纯化水溶解,按照临床人推荐剂量的4给每组实验性白癜风豚鼠模型灌胃,以模拟临床药物治疗。
实验周期结束后,分别进行肉眼观察与血液指标测量:
肉眼观察:肉眼观察对照组、实验组1、实验组2、实验组3、实验组4、实验组5、实验组6的豚鼠表皮颜色与空白组之间的差别;疗效判断标准:以豚鼠脱毛中心3cm2为一观察单位,若观察区色素基本恢复正常则为优,若观察区出现色素面积大于百分之五十则为良,若观察区出现色素面积小于百分之五十则为中,若观察区皮肤呈苍白或白斑状则为差;结果如下表1所示:
表1白癜风专用型临床营养配方对白癜风豚鼠模型的治疗效果肉眼观察
血液指标测量:取对照组、实验组1、实验组2、实验组3、实验组4、实验组5、实验组6以及空白组的豚鼠血浆适量,分别按照CHE(胆碱脂酶)、MAO(单胺氧化酶)、MDA(丙二醛)的试剂盒要求进行操作并测定,测定血浆中CHE、MAO的活力以及MDA含量,测定结果如下表2所示:
表2白癜风专用型临床营养配方对白癜风豚鼠模型的治疗效果血液指标测量
组别 | 例数 | CHE(μ/h·ml) | MAO(μ/h·ml) | MDA(nmol/ml) |
空白组 | 20 | 41.7±4.6 | 74.9±13.4 | 2.78±3.20 |
对照组 | 20 | 64.2±9.0 | 129.8±1.9 | 5.82±1.29 |
实验组1 | 20 | 43.2±16.1 | 76.8±14.0 | 3.29±1.62 |
实验组2 | 20 | 42.9±2.9 | 78.9±5.1 | 3.12±5.16 |
实验组3 | 20 | 43.7±1.9 | 80.0±5.3 | 3.53±4.13 |
实验组4 | 20 | 48.5±1.5 | 83.9±4.8 | 3.58±1.06 |
实验组5 | 20 | 52.1±10.7 | 78.9±8.8 | 4.38±0.49 |
实验组6 | 20 | 47.6±6.1 | 92.3±16.2 | 4.08±2.73 |
由上表1和表2结果可知,采用药物治疗的同时采用本发明的白癜风专用型临床营养配方有助于豚鼠皮肤黑色素增加;能够使豚鼠血液中CHE、MAO活性降低,使MDA含量减少,有助于改善治疗时豚鼠的精神状态,缓解药物治疗导致的毒副作用的伤害,提高治疗效果。
由上述实施例可知,本发明的白癜风专用型临床营养配方中各组分相互配合,为白癜风患者提供合理、全面、均衡的营养支持,以改善白癜风患者的身体状态、保持患者身体质量的稳定、加强免疫应答能力,同时添加的膳食纤维、膳食精华、药食同源成分以及新资源食品等具有改善新陈代谢、抗氧化、调节情绪、缓解精神压力、利于皮肤组织修复的功能,作为白癜风患者的临床治疗的营养辅助,有助于为白癜风患者提供手术前营养支持和手术后组织修复的营养辅助治疗,并缓解治疗白癜风的药物的毒副作用以及患者的心理和精神上的负担。
以上对本发明的具体实施例进行了详细描述,但其只作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对该实用进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (10)
1.一种白癜风专用型临床营养配方,其特征在于,包括如下组分及其重量份数:20-26份蛋白质、32-44份碳水化合物、16-22份膳食纤维、0.01-0.04份微量元素、0.005-0.03份脂溶性维生素、0.1-0.25份水溶性维生素、0.1-11份膳食精华、0.2-18份药食同源成分以及0.01-1.1份新资源食品;
其中,所述药食同源成分包括茯苓、栀子、黑芝麻、薄荷、桔梗、山药、牡蛎、桃仁、覆盆子、枸杞子中的至少一种;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、小麦低聚肽、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
2.根据权利要求1所述的白癜风专用型临床营养配方,其特征在于,所述膳食纤维至少包括菊粉,所述菊粉的重量份数为10-16份。
3.根据权利要求1所述的白癜风专用型临床营养配方,其特征在于,所述微量元素包括铁、锌和铜。
4.根据权利要求3所述的白癜风专用型临床营养配方,其特征在于,所述微量元素中铜的重量份数为0.0003-0.001份,锌的重量份数为0.01-0.02份。
5.根据权利要求1所述的白癜风专用型临床营养配方,其特征在于,所述膳食精华包括6-8份大豆粉、0.1-1份南瓜籽粉、0.1-0.5份海带粉、0.1-0.5份香菇粉、0.1-0.5份黑木耳粉、0.1-0.5份猪肝粉。
6.根据权利要求1所述的白癜风专用型临床营养配方,其特征在于,所述药食同源成分包括黑芝麻、覆盆子、枸杞子、桔梗、山药、牡蛎、桃仁。
7.根据权利要求6所述的白癜风专用型临床营养配方,其特征在于,所述药食同源成分中各组分的重量份数为:黑芝麻10-15份、覆盆子0.1-0.5份、枸杞子0.1-0.5份、桔梗0.1-0.5份、山药0.1-0.5份、牡蛎0.1-0.5份、桃仁0.1-0.5份。
8.根据权利要求1所述的白癜风专用型临床营养配方,其特征在于,所述新资源食品包括γ-氨基丁酸和小麦低聚肽。
9.根据权利要求8所述的白癜风专用型临床营养配方,其特征在于,所述新资源食品中各组分的重量份数为:γ-氨基丁酸0.01-0.1份、小麦低聚肽0.1-1份。
10.一种如权利要求1所述的白癜风专用型临床营养配方的制备方法,其特征在于,包括如下步骤:
步骤1,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤2,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤3,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳食精华以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤4,将步骤1~3所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤5,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~3的顺序可相互更换。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237134.XA CN109497563A (zh) | 2018-10-23 | 2018-10-23 | 白癜风专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237134.XA CN109497563A (zh) | 2018-10-23 | 2018-10-23 | 白癜风专用型临床营养配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109497563A true CN109497563A (zh) | 2019-03-22 |
Family
ID=65746158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811237134.XA Pending CN109497563A (zh) | 2018-10-23 | 2018-10-23 | 白癜风专用型临床营养配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109497563A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111840560A (zh) * | 2020-07-24 | 2020-10-30 | 广州医科大学 | 钙离子载体在白癜风治疗中的应用 |
CN115006431A (zh) * | 2022-08-09 | 2022-09-06 | 云南三江本草药业有限公司 | 菲牛蛭在制备治疗白癜风的药物中的应用及药物制剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN107242550A (zh) * | 2017-06-29 | 2017-10-13 | 上海复旦奥医医学科技有限公司 | 一种男性不育专用型临床营养配方及其制备方法 |
CN108013454A (zh) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | 妇科炎症专用型临床营养配方及其制备方法 |
CN108077911A (zh) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | 一种癫痫患者专用型临床营养配方及其制备方法 |
CN108308597A (zh) * | 2017-12-05 | 2018-07-24 | 上海奥医生物医药科技有限公司 | 一种营养不良专用型临床营养配方及其制备方法 |
CN108651988A (zh) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | 肾病透析专用型临床营养配方及其制备方法 |
-
2018
- 2018-10-23 CN CN201811237134.XA patent/CN109497563A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN107242550A (zh) * | 2017-06-29 | 2017-10-13 | 上海复旦奥医医学科技有限公司 | 一种男性不育专用型临床营养配方及其制备方法 |
CN108308597A (zh) * | 2017-12-05 | 2018-07-24 | 上海奥医生物医药科技有限公司 | 一种营养不良专用型临床营养配方及其制备方法 |
CN108013454A (zh) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | 妇科炎症专用型临床营养配方及其制备方法 |
CN108077911A (zh) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | 一种癫痫患者专用型临床营养配方及其制备方法 |
CN108651988A (zh) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | 肾病透析专用型临床营养配方及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111840560A (zh) * | 2020-07-24 | 2020-10-30 | 广州医科大学 | 钙离子载体在白癜风治疗中的应用 |
CN111840560B (zh) * | 2020-07-24 | 2021-09-03 | 广州医科大学 | 钙离子载体在白癜风治疗中的应用 |
CN115006431A (zh) * | 2022-08-09 | 2022-09-06 | 云南三江本草药业有限公司 | 菲牛蛭在制备治疗白癜风的药物中的应用及药物制剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1037590B1 (en) | Soy formulations and their use for promoting health | |
JP6873517B2 (ja) | 成年女性、高齢者及び亜健康状態の人々に適用できる健康保持製品組成物 | |
CN101473953B (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
CN106983136A (zh) | 一种产褥期调理专用型临床营养配方及其制备方法 | |
CN102172269B (zh) | 一种具有美容作用阿胶组合食品 | |
CN108013454A (zh) | 妇科炎症专用型临床营养配方及其制备方法 | |
CN110447902B (zh) | 一种具有减肥功效的组合物 | |
WO2011060585A1 (zh) | 含有五色果蔬精华的咀嚼片剂及其制备方法 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
CN101274078A (zh) | 一种天然植物提取物及其制备方法和应用 | |
CN105124605A (zh) | 一种保健咀嚼片及其制备方法 | |
CN108887564A (zh) | 一种硒蛋白杂粮粉配方及其制备方法 | |
CN109349618A (zh) | 便秘专用型临床营养配方及其制备方法 | |
CN107373672A (zh) | 一种月经不调女性专用型临床营养配方及其制备方法 | |
WO2008067315A1 (en) | Therapeutic composition from goji (lycium barbarum l.), methods of making and using | |
CN109497563A (zh) | 白癜风专用型临床营养配方及其制备方法 | |
JP2005500074A (ja) | 女性/妊婦用の薬草由来の栄養補助製剤およびその調製方法 | |
CN106173871A (zh) | 一种降三高水饺及其制备方法 | |
CN108782679A (zh) | 一种减肥干预代餐饼干及其制备方法 | |
CN109275856A (zh) | 一种灵芝食品 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |